David has interests in cancer biology, molecular genetics, and cell biology. His focuses to date have been on molecular mechanisms of anti-cancer therapeutics, as well as drug resistance in pancreatic cancer.
David joined ARU as a full-time Research Assistant in January 2022 after completing his MSc in Applied Bioscience at ARU in 2021. He is currently working on a collaborative project investigating a novel anti-cancer therapeutic monoclonal antibody with Medannex Ltd.
Prior to this David worked as an associate practitioner for the Point of Care Team at Addenbrooke's hospital, performing diagnostic biochemistry, haematology, and RNA amplification assays.
David’s undergraduate degree was in Human Biology at the University of Birmingham, completing an undergraduate project investigating meiotic recombination hotspots.
David’s current research focus is investigating the mechanism of action of MDX-124, a humanised monoclonal antibody anti-cancer therapy, as well as exploring its ability to overcome chemotherapeutic resistance. Utilising colorimetric, fluorescent microscopy, flow-cytometry, imaging flow cytometry and immuno-assays to determine how this therapeutic mediates its effects on cell survival in pancreatic, colorectal, breast and ovarian cancer.
MSc Applied Bioscience
MSc Applied Bioscience, Anglia Ruskin University, 2021
BSc (Hons) Human Biology, University of Birmingham, 2014